Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Pentobarbital. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.96 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.96 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.96 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | MMP9 | P14780 | 2/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentobarbital SCHEMBL3695587 | 1.00 | CYP3A4 (0.96) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL26056 | 1.00 | CYP3A4 (0.96) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL7639355 | 1.00 | CYP3A4 (0.96) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL9476253 | 1.00 | CYP3A4 (0.96) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL735353 | 0.98 | CYP3A4 (1.00) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL24966 | 0.98 | CYP3A4 (1.00) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL2376470 | 0.98 | CYP3A4 (1.00) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL1256614 | 0.96 | CYP3A4 (0.96) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL3245534 | 0.96 | CYP3A4 (0.96) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL4207760 | 0.96 | CYP3A4 (0.96) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 52604 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031133-A | Method for constructing anal fistula model based on rat perianal chronic infectious wound surface | 南方医科大学 | 2026-05-15 | — | — | CN | claimed |
| US-20260013482-A1 | METHOD FOR CONSTRUCTING AN ANIMAL MODEL OF OPEN-ANGLE GLAUCOMA | THE SECOND XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY (CN) | 2026-01-15 | — | — | US | claimed |
| CN-119595795-B | Platelet protein ultrafiltration affinity mass spectrum-based anti-platelet active ingredient screening method | 上海中医药大学 | 2025-06-10 | — | — | CN | claimed |
| CN-120053134-A | Method for chronic continuous administration in brain chamber of experimental animal | 北京伽拓医药研究有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-120021588-A | In-situ PDX model construction method for pseudo-myxoma of peritoneum | 中南大学湘雅医院 | 2025-05-23 | — | — | CN | claimed |
| CN-119969338-A | Construction method of ocular hypertension animal model | 中南大学湘雅二医院 | 2025-05-13 | — | — | CN | claimed |
| CN-119949273-A | Naked mole rat immunodeficiency animal model building method | 中国人民解放军海军军医大学 | 2025-05-09 | — | — | CN | claimed |
| US-20250144025-A1 | ANTI-ABUSE GELLED PHARMACEUTICAL COMPOSITIONS | VITUX GROUP AS (NO) | 2025-05-08 | — | — | US | claimed |
| CN-119908334-A | Method for manufacturing experimental model of late-onset AD mice | 扬州大学 | 2025-05-02 | — | — | CN | claimed |
| CN-119857001-A | Construction method of lung injury animal model after inhalation of radioactive dust | 中国辐射防护研究院 | 2025-04-22 | — | — | CN | claimed |
| EP-0746342-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES LTD. (US) | 1996-12-11 | — | — | EP | claimed |
| EP-0729748-A1 | PROCESS FOR PRODUCING STABLE MEDICINAL COMPOSITION, AND PHARMACEUTICAL PREPARATION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1996-09-04 | — | — | EP | claimed |
| US-5518730-A | Biodegradable controlled release flash flow melt-spun delivery system | FUISZ TECHNOLOGIES LTD. (US) | 1996-05-21 | — | — | US | claimed |
| EP-0746342-A4 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES LTD (US) | 1996-01-11 | — | — | EP | claimed |
| WO-1993024154-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES, LTD. (US) | 1993-12-09 | — | — | WO | claimed |
| US-4508715-A | DOPAMINE ANTAGONISTS;OVERDOSE TREATMENT | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1985-04-02 | — | — | US | claimed |
| EP-0105361-A1 | ANTAGONISM OF CENTRAL NERVOUS SYSTEM DRUGS BY THE ADMINISTRATION OF 4-AMINOPYRIDINE ALONE OR IN COMBINATION WITH OTHER DRUGS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1984-04-18 | — | — | EP | claimed |
| WO-1983003541-A1 | ANTAGONISM OF CENTRAL NERVOUS SYSTEM DRUGS BY THE ADMINISTRATION OF 4-AMINOPYRIDINE ALONE OR IN COMBINATION WITH OTHER DRUGS | UNIV GEORGIA RES FOUND (US) | 1983-10-27 | — | — | WO | claimed |
| US-4244941-A | POROUS COATING OF COMPRESSED POWDERS ALLOWS CONSTANT RELEASE OF CORE SUBSTANCE | GIST-BROCADES N.V. (NL) | 1981-01-13 | — | — | US | claimed |
| US-4235236-A | Device for dispensing drug by combined diffusional and osmotic operations | ALZA CORPORATION (US) | 1980-11-25 | — | — | US | claimed |